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Prospects for combined use of oncolytic
viruses and CAR T-cells
Adam Ajina1 and John Maher2,3,4*
Abstract
With the approval of talimogene laherparepvec (T-VEC) for inoperable locally advanced or metastatic malignant
melanoma in the USA and Europe, oncolytic virotherapy is now emerging as a viable therapeutic option for cancer
patients. In parallel, following the favourable results of several clinical trials, adoptive cell transfer using chimeric
antigen receptor (CAR)-redirected T-cells is anticipated to enter routine clinical practice for the management of
chemotherapy-refractory B-cell malignancies. However, CAR T-cell therapy for patients with advanced solid
tumours has proved far less successful. This Review draws upon recent advances in the design of novel oncolytic
viruses and CAR T-cells and provides a comprehensive overview of the synergistic potential of combination
oncolytic virotherapy with CAR T-cell adoptive cell transfer for the management of solid tumours, drawing particular
attention to the methods by which recombinant oncolytic viruses may augment CAR T-cell trafficking into the
tumour microenvironment, mitigate or reverse local immunosuppression and enhance CAR T-cell effector function
and persistence.
Keywords: Oncolytic virus, Chimeric antigen receptor, CAR T-cell, Adoptive cell transfer, Combination strategies,
Synergism, Solid tumours
Background
This review focuses on the prospects for the synergistic
combinatorial use of two distinct immunotherapeutic
modalities – adoptive cell transfer (ACT) of chimeric
antigen receptor (CAR)-expressing T-cells and oncoly-
tic virotherapy. The latter has a long historical pedigree
dating back to the 1950s, but has only very recently
entered into routine clinical practice. This followed the
approval of talimogene laherparepvec (or T-VEC), a re-
combinant granulocyte macrophage colony-stimulating
factor (GM-CSF)-containing human herpes simplex
type I virus (HSV-1), for inoperable locally advanced or
metastatic malignant melanoma based upon compelling
efficacy data from the phase III OPTiM trial [1]. T-VEC
is currently being investigated in a number of early and
late phase clinical trials in melanoma and other solid
malignancies. These include its co-administration with
immune checkpoint inhibitors targeted against pro-
grammed cell death protein 1 (PD-1; e.g. pembrolizumab
or nivolumab), cytotoxic T lymphocyte antigen 4 (CTLA-4;
e.g. ipilimumab) [2] or the combination of T-VEC with
systemic chemotherapy [3] or radiotherapy [4, 5]. Several
other oncolytic viruses (OVs) are also undergoing clinical
evaluation (e.g. GL-ONC1 [6], vvDD [7]).
Clinical use of CAR T-cell therapy on the other hand
has emerged within the last decade. This has followed
on from the successful use of tumour infiltrating
lymphocyte (TIL)-based ACT for patients with
advanced melanoma, originally developed by Rosenberg
and colleagues at the National Cancer Institute (NCI)
in the late 1980s [8]. Autologous CAR T-cell therapy
targeting the B-cell-specific cell surface protein CD19
have induced lasting and deep remissions in patients
with refractory B-cell malignancies, such as acute
lymphoblastic leukaemia (ALL) or chronic lymphocytic
leukaemia (CLL) [9]. Several Phase II clinical trials
investigating second generation anti-CD19 CARs have
now reported and these agents are expected to enter
routine clinical practice imminently. However, the
development of effective CAR T-cell therapies for solid
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tumours has proved far less straightforward, owing to
several critical obstacles pertaining to safety and potency.
This review attempts to present opportunities to over-
come these issues by highlighting potential for synergistic
immunotherapy with oncolytic virotherapy.
Oncolytic virotherapy: the story so far
The development of genetically engineered OVs came
to the fore in the 1990s with the first clinical trials of
recombinant adenoviruses, such as ONYX-015 [10].
For a long time, it was assumed that the dominant
mechanism underpinning the anti-cancer effect of these
agents stemmed from their oncolytic potential. It is
now apparent, however, that the lysis of virally infected
cancer cells plays a relatively indirect role in inducing
tumour regression and long-term clinical benefit in
most patients. Instead, it has become clear that clinical
efficacy of OVs (such as T-VEC) is strongly dependent
upon their ability to convert tumours into living “vaccine
factories”. These provide immunological “danger signals”
that include small molecules (e.g. uric acid [11] and ad-
enosine triphosphate (ATP)), and protein mediators such
as high-mobility group box 1 (HMGB1) [12] and type I
interferon (IFN) signalling [13]. By this means, OV infec-
tion results in enhanced tumour-associated antigen pres-
entation (due to neo-antigen spreading), improved T-cell
and natural killer (NK) cell trafficking into the tumour
microenvironment (TME) and enhanced effector function,
leading to a “bystander effect” at local and distant sites of
disease. Efficacy of oncolytic virotherapy is therefore
dependent upon a complex interplay between functional
innate and adaptive immune cells within the patient and
more specifically within the TME itself. Many solid
tumours present a significant barrier to this process
whereby the TME is either non-permissive to entry of ef-
fector immune cells or exerts immunosuppressive effects
on those cells that do manage to gain access [14]. The
ability of recombinant OVs to modulate the TME is now
being exploited further by rationally inserting transgenes
to encode immunostimulatory cytokines, chemokines or
co-stimulatory molecules into viral virulence genes, thus
fulfilling a dual strategy of optimising tumour tropism and
specificity. Oncolytic viruses are therefore highly attractive
agents to use in combination with cellular therapies when
targeting solid tumours.
A wide variety of OV vectors spanning numerous
viral families have been identified and developed [13].
Pre-clinical and clinical studies are currently evaluating
the potential of oncolytic adenoviruses, herpesviruses,
poxviruses, picornaviruses (including coxsackievirus,
polioviruses and Seneca Valley virus), paramyxoviruses
(including measles viruses and Newcastle disease virus
(NDV)), reoviruses, parvoviruses and rhabdoviruses
(e.g. vesicular stomatitis virus (VSV)). The number of
clinical trials evaluating OVs either alone or in combin-
ation with other therapies has expanded rapidly and
these are summarised in detail in Table 1. Globally, two
viruses, T-VEC and H101 have now achieved regulatory
approval. H101 is a genetically modified oncolytic
adenovirus that was approved in China in November
2005 for the treatment of nasopharyngeal carcinoma in
combination with systemic chemotherapy [15]. The
diversity of available OVs, each with their own hall-
marks of tumour tropism and specificity, virulence and
oncolytic potential allows for the nuanced and optimal
selection of OVs for combined use with cellular therapies
such as CAR T-cell therapy. Furthermore, many OVs have
undergone extensive iterative laboratory-based study
during the development of anti-viral vaccines over many
decades. This provides reassurance with regards to safety
and tolerability following administration in human sub-
jects. Oncolytic strains of vaccinia virus – a large, com-
plex, enveloped poxvirus – have the longest and most
extensive history of administration in humans of any
known virus due to their use in the eradication of small-
pox during the middle of the last century [16].
As gene-manipulating technologies have moved to the
forefront of bio-scientific research, great strides have
been made in understanding and delineating the mecha-
nisms of tumour tropism and specificity. Although this
remains incompletely understood, it is recognised that
many OVs are dependent upon cancer cells providing a
nucleotide-rich environment and expressing relatively
high levels of key molecules conducive to viral genomic
replication, relative to normal tissue. Several mecha-
nisms may underlie the tumour specificity of OVs. First,
some OV achieve preferential viral entry into cancer
cells by binding to cell surface molecules that are more
highly expressed by certain tumours. This is illustrated
by the ability of many OV strains of coxsackievirus to
bind to intercellular adhesion molecule 1 (ICAM-1),
which is a cell adhesion molecule that is over-expressed
in many tumours [17]). Alternatively, OVs may exploit
specific aberrant signalling pathways in cancer cells
through one of many mechanisms. For example, vaccinia
virus replication is favoured by heightened epidermal
growth factor receptor (EGFR)-RAS signalling, as found
in many solid tumours [18]. Similarly, overexpression of
B-cell lymphoma (BCL) pro-survival proteins (such as
BCL-xL) is targeted by NDV, which is able to continuously
replicate and induce syncytium formation in apoptosis-
resistant cells [19] while p53 deficient cancer cells are
more susceptible to E1B deleted adenoviral strains [20]).
The absence or impairment in cancer cells of type I IFN
signalling renders these cells more susceptible to several
OV strains [21]. Alternatively, some OV types exhibit
preferential sequestration by the tumour microvascula-
ture, as is seen with many vaccinia strains [22].
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Table 1 List of clinical trials evaluating OVs in solid tumours
Table updated and amended from [13]. Clinical trials highlighted in yellow are currently recruiting or not yet recruiting patients as of 28th August
2017 on clinicaltrials.gov. AdMA3 Adenovirus with transgenic MAGE-A3 insertion, AML acute myeloid leukaemia, AT/RT atypical teratoid rhabdoid
tumour, BCG Bacillus Calmette-Guérin, CEA carcinoembryonic antigen, CNS central nervous system, CRT chemoradiotherapy, EGFR epidermal growth
factor receptor, GM-CSF granulocyte–macrophage colony-stimulating factor, HAI hepatic arterial infusion, HCC hepatocellular carcinoma, hNIS human
sodium iodide symporter, HNSCC head and neck squamous cell carcinoma, IFN-β interferon beta, IP intraperitoneal, IPL intrapleural, IT intratumoural,
IV intravenous, MAGE-A3, melanoma associated antigen 3, MSC mesenchymal stem cells, MSI microsatellite instability, MV measles virus, NDV
Newcastle disease virus, NSCLC non-small-cell lung cancer, PDAC pancreatic ductal adenocarcinoma, PNET primitive neuroectodermal tumour, RCC
renal cell carcinoma, RGD Arg-Gly-Asp motif, RT radiotherapy, SCC squamous cell carcinoma, SCLC small cell lung cancer, STS soft tissue sarcoma, SVV,
Seneca Valley virus, TACE transarterial chemoembolization, TK thymidine kinase, TNBC triple negative breast cancer, US11 unique short 11
glycoprotein, VSV vesicular stomatitis virus
Ajina and Maher Journal for ImmunoTherapy of Cancer  (2017) 5:90 Page 3 of 27
Many OVs such as adenoviruses and poxviruses have
sufficiently large genomes to facilitate the insertion of
foreign genes. The ability of recombinant OVs to modu-
late the TME is being exploited further by rationally
inserting transgenes to encode immunostimulatory cyto-
kines, chemokines or co-stimulatory molecules into viral
virulence genes, thus fulfilling a second strategy aside
from optimising tumour tropism and specificity [13].
Specifically, recombinant OVs can circumvent many of
the tumour’s mechanisms of immune escape (e.g. by
enhancing type I IFN signalling, upregulating major
histocompatibility complex (MHC) class I expression on
cancer cells [23], targeting enhanced transforming
growth factor beta (TGF-β)/Wnt/β-catenin signalling
and its negative impact upon antigen presentation [24]
or by delivering inhibitors of active immunosuppressive
pathways in the TME e.g. prostaglandin E2 (PGE2) [25]
or adenosine A2a receptors (A2ARs). They may also de-
liver a therapeutic payload designed to enhance their
oncolytic potential (e.g. apoptotic proteins such as apop-
tin [26] or death receptor ligands [27]).
Oncolytic viruses may be administered systemically or
via intra-tumoural injection. This facilitates the broad
application of OVs to specific combinatorial immuno-
therapeutic strategies. Both methodologies are associated
with specific advantages and disadvantages. For example,
the systemic delivery of OVs may be limited by the host’s
defences. Viral particles may be sequestered by neutralis-
ing antibodies or by complement activation within the
circulation; they may be filtered by the lungs, liver or
spleen; and they may encounter physical barriers that
limit their escape from the vascular compartment or
prevent their entry into the TME [28]. Local instillation
of OV into the tumour may bypass many of these
barriers. However, due to their location many tumours
are not immediately accessible to targeted OV delivery.
They may be located deep within the body or in close
proximity to critical structures. The systemic delivery of
OVs also affords a method of targeting multiple meta-
static deposits simultaneously. Several techniques have
been explored in order to optimise the systemic delivery
of OVs, such as by using cytokine preconditioning [29],
complement inhibitors [30], immunomodulatory agents
such as cyclophosphamide [31, 32], B-cell depleting
agents such as rituximab or with plasmapheresis [33].
Transduced cytotoxic T-cells containing OV DNA have
also been utilised as “Trojan horses” for ACT [34].
Currently there remain many stumbling blocks to the
use of OVs as monotherapies in cancer patients. Aside
from recent success seen in the field of malignant
melanoma, only modest potency has been demonstrated
in patients with other advanced solid tumours. One issue
relates to the presence of pre-existing anti-viral anti-
bodies in patients who have previously been vaccinated
with similar vectors [28]. And in those who have not
been vaccinated, the administration of an OV typically
leads to the rapid development of immunity and viral
clearance by neutralizing antibodies and complement.
Other barriers to the efficient systemic delivery of OVs
include aberrant tumour vasculature, mis-localisation
and sequestration in non-target tissues and inadequate
extravasation from the circulation [35]. Due to their
putative immune-mediated mechanism of action, they
require a relatively intact host innate and adaptive
immune system. This is often compromised in cancer
patients, whose relative immunodeficiency may also give
rise to safety concerns due to unconstrained infection in
non-target tissues [36]. A number of practical concerns
have also curtailed their rapid development and the
study of combination strategies may be impacted by the
lack of OVs that have been approved for clinical practice.
Technical and logistical challenges also exist that have
limited the clinical evaluation of these agents outside of
large academic centres.
CAR T-cell immunotherapy: the story so far
Immunotherapy using CAR-engineered T-cells is un-
doubtedly one of the most innovative therapeutic strat-
egies to have emerged among those that either co-opt or
augment an individual’s capacity to mount an effective
immune response against cancer. Chimeric antigen
receptors are recombinant cell surface fusion molecules
that couple the binding of a native tumour-specific or
tumour-associated cell surface antigens (TSAs or TAAs)
to the delivery of a bespoke T-cell-activating signal [37, 38].
CAR T-cells have proved efficacious in the management of
patients with haematological malignancies and, in parallel
with T-cell receptor (TCR)-gene modified antigen-specific
T-cells, are currently being evaluated in patients with a
variety of solid tumours. CAR T-cell therapy provides a
number of advantages over TIL or TCR-engineered ACT.
Firstly, CAR T-cells bypass the requirement for peptide
processing, HLA expression and antigen presentation by
cancer cells [37]. Given that the loss of MHC class I expres-
sion and the downregulation of proteasomal antigen
processing are recognised as mechanisms of acquired
resistance to cancer immunotherapy with immune check-
point blockade [39] or standard ACT, this ability by CARs
to circumvent the machinery of antigen presentation
becomes particularly attractive. As a result, CAR T-cells
can recognise antigen on any human leukocyte antigen
(HLA) background, in contrast to TCRs which must be
matched to a patient’s HLA haplotype [40]. Chimeric anti-
gen receptors can also target non-protein TAAs such as
carbohydrate or glycolipid structures [37]. Unlike TCRs
however, they are limited to targeting cell surface rather
than cytoplasmic or nuclear TAAs [40]. Whilst this does, to
some extent, limit the potential repertoire of CAR targets,
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our increasing understanding of the “surfaceome” of both
tumours and normal tissue is now providing a plethora of
targets [41]. A number of these targets are currently being
explored in early phase clinical trials and are summarised
in Table 2. The ability to genetically engineer T-cells lends
itself to limitless customisation and adaptation. In concert
with the development of novel sensing and CAR-control
technologies, this has the potential to inform the develop-
ment of logic-gated stimulatory and inhibitory CAR circuits
for the algorithmic targeting of tumours [42].
The design of CARs has undergone several iterative
steps since their original description in 1989 by Eshhar
and colleagues [43]. First generation CARs (termed “T-
bodies”) incorporated an antigen-binding domain, such as
an antibody-derived single chain variable fragment (scFv)
or endogenous receptor ligand coupled to a CD8, CD4,
CD25 or CD16 transmembrane domain and a CD3ζ or Fc
receptor γ intracellular domain. Antigen engagement by
the CAR induces the formation of an immune synapse
with subsequent downstream signalling through a cascade
of TCR-associated kinases. Ultimately, this leads to the
transfer of cell-lysis inducing molecules (such as perforin
and granzyme B) into the target cell, causing cytotoxicity
as well as the secretion by the CAR T-cell of immunosti-
mulatory cytokines that facilitate T-cell proliferation and
activation in an autocrine and paracrine fashion [37].
However, first generation CAR T-cells failed to elicit a
robust cytokine response with repeated antigen exposure
and were susceptible to rapid onset of anergy [44]. Second
generation CARs express both activating and co-
stimulatory intracellular domains in cis and induce signal-
ling that more closely mimics that of physiological TCR.
In these receptors, a CD3ζ chain is fused to the cyto-
plasmic domain of a co-stimulatory receptor such as
CD28, 4-1BB, OX40, ICOS or DAP10. Third generation
CARs which are yet to demonstrate a clear improve-
ment in efficacy incorporate three or more signalling
domains e.g. CD28 and 4-1BB or CD28 and OX40,
together with a source of signal 1 such as CD3ζ [45].
These CAR constructs are illustrated in Fig. 1.
Table 2 List of clinical trials evaluating CARs in solid tumours
Table updated and amended from [223]. Clinical trials highlighted in yellow are currently recruiting or not yet recruiting patients as of 28th August 2017 on
clinicaltrials.gov. CCR chimeric costimulatory receptor, CD19t truncated CD19, CEA carcinoembryonic antigen, CHMC City of Hope Medical Centre, CMV
cytomegalovirus, c-MET c-mesenchymal-epithelial transition, CMH Children’s Mercy Hospital, CNS central nervous system, CRT chemoradiotherapy, CRUK Cancer
Research UK, CTL cytotoxic T-lymphocyte, DNR dominant negative receptor, EBV Epstein Barr virus, EGFRt truncated EGFR, EGFRvIII epidermal growth factor
receptor variant III, FAP fibroblast activation protein, FHCRC Fred Hutchinson Cancer Research Centre, fIL-12 feline interleukin-12, FRα folate receptor alpha, GR
glucocorticoid receptor, HAI hepatic arterial infusion, HCC hepatocellular carcinoma, HER2 human epidermal growth factor receptor 2, HNSCC head and neck
squamous cell carcinoma, HSV herpes simplex virus, HyTK hygromycin phosphotransferase-HSV thymidine kinase, IL-2 interleukin-2, IL-13 interleukin-13, IP
intraperitoneal, IPL intrapleural, IT intratumoural, IV intravenous, MSKCC Memorial Sloan-Kettering Cancer Centre, NCI National Cancer Institute, NSCLC non-small-cell lung
cancer, PDAC pancreatic ductal adenocarcinoma, RCC renal cell carcinoma, RWM Roger Williams Medical Centre, SCH Shanghai Cancer Hospital, SS safety switch, TCR T-cell
receptor, TK thymidine kinase, TNBC triple negative breast cancer, UPenn University of Pennsylvania
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Second generation CARs have demonstrated signifi-
cant anti-cancer potency in pre-clinical and clinical
models. On 30th August 2017 the United States Food
and Drug Administration (FDA) approved the use of
tisagenlecleucel (CTL019), a CD19-directed CAR T-cell
product, for the treatment of patients up to 25 years of
age with B-cell precursor ALL that is refractory or in
second or later relapse. Approval was based on a num-
ber of early phase clinical trials including the pivotal
single-arm, open-label, multicentre phase II ELIANA
trial, which demonstrated that 83% of patients achieved
complete remission (CR) or CR with incomplete blood
count recovery within 3 months of treatment [46]. This
agent, alongside other CAR products, has also been
found to have considerable efficacy in other haemato-
logical malignancies such as chronic lymphocytic leukae-
mia (CLL) and lymphoma. Interim analysis presented at
the International Conference on Malignant Lymphoma
(ICML) meeting in Lugano, Switzerland, of the phase II
JULIET trial evaluating tisagenlecleucel in adult patients
with relapsed or refractory diffuse large B-cell lymphoma
(DLBCL) revealed a 3 month overall response rate
(ORR) of 45% with 37% achieving a complete response
(CR) [47]. Results from the primary analysis of the phase
II ZUMA-1 trial evaluating KTE-C19 (axicabtagene
ciloleucel or axi-cel) in adult patients with relapsed or
refractory DLBCL, primary mediastinal B cell lymphoma
(PMBCL) or transformed follicular lymphoma were also
presented at ICML. Treatment with axicabtagene
ciloleucel was associated with an ORR of 82% with 39%
in CR at a median follow-up of 8.7 months, a rate 7-fold
higher compared to historical controls [48]. Further-
more, CAR T-cells with a central memory or stem-like
phenotype can persist and remain efficacious for pro-
longed periods of time [49], as demonstrated in patients
with durable remissions and B-cell aplasia following
CD19-directed CAR T-cell therapy at a number of insti-
tutions such as the University of Pennsylvania [50, 51],
Memorial Sloan-Kettering Cancer Centre [52, 53] and
the National Cancer Institute [54, 55].
Whilst CAR T-cell immunotherapy has proved to be
highly efficacious in patients with B-cell malignancies,
this has not yet been reproduced in patients with solid
tumours, which present several additional obstacles to
success. These include: (i) a greater risk of unacceptable
toxicity (due to potential for “on target off tumour”
effects, caused by targeting TAAs expressed in multiple
tissues) [56]; (ii) paucity of “dispensable antigens”
expressed by solid tumours, unlike CD19+ B-cells [57];
(iii) poor trafficking of CAR T-cells into the TME [57]
and (iv) impaired CAR T-cell effector function within
the TME [58]. Another problem relates to the inherent
heterogeneity of solid tumours, both temporally and
spatially. Such variability is liable to result in incomplete
tumour targeting by CARs and acquired resistance due
to antigen loss [44]. In addition, the diversity of TAAs in
solid tumours and distinct subtypes necessitates the
design of suitably selective CARs for each disease entity.
The safety of CAR T-cell ACT remains a particular
concern. Unfortunately, a number of clinical trials inves-
tigating CAR T-cell therapy have been marred by reports
of fatalities due to severe cytokine release syndrome
(CRS), macrophage activation syndrome (MAS) or
neurotoxicity [59]. The latter, in particular, is poorly
understood and has sometimes proved resistant to pre-
vention or treatment with supportive strategies. There
Fig. 1 CAR design. CARs exist as dimers and consist of an ectodomain (typically comprising an scFv for target binding joined to an extracellular spacer e.g.
IgG1 CH2CH3); a transmembrane domain (TMD); and a signalling endodomain. CAR design has evolved from first generation constructs linking the scFV to
a CD3ζ or FcεRIγ-derived immunoreceptor tyrosine-based activation motif (ITAM) to second and third generation constructs, where the CARs endodomain
contains one or two or more additional costimulatory molecules (such as CD28, 4-1BB, ICOS or OX40) [37]. Fourth generation CAR T-cells (not illustrated)
termed TRUCKs are further modified with a constitutive or inducible expression cassette for a transgenic protein (such as IL-12), which is released by the
CAR T-cells following receptor binding [101]
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are also theoretical fears of insertional mutagenesis and
the development of T-cell malignancy due to the use of
integrating viral vectors, particularly those that exhibit
powerful enhancer function [60].
The potential to cause “on target off tumour” toxicity
is particularly pertinent to the design of CARs targeting
TAAs expressed by solid tumours. This danger was
highlighted by the death of a patient in a phase I first in-
man clinical trial evaluating a third generation anti-
HER2 CD28-4-1BB-CD3ζ CAR. In the aftermath of this
case it was postulated that these potent HER2-directed
CAR T-cells were able to recognise physiological low
level HER2 protein expressed in normal lung tissue dur-
ing their first pass passage through the pulmonary vas-
culature, leading to an inflammatory cytokine cascade,
pulmonary toxicity and ultimately multi-organ failure
[61]. More recently, numerous techniques have been
explored to mitigate this risk and CAR products are cur-
rently in clinical development that incorporate inducible
safety switches that can be triggered at will. Alongside
the well-characterised herpes simplex virus-thymidine
kinase (HSV-TK) / ganciclovir suicide gene system, CAR
T-cells have been engineered to express an inducible
caspase 9 gene (CaspaCIDe®) that induces apoptosis in
the presence of rimiducid, a lipid-permeable tacrolimus
analogue with homodimerizing activity [62]. An alterna-
tive strategy is to co-express a truncated cell surface pro-
tein, such as human epidermal growth factor (EGFR)
that can be targeted by a pharmaceutical-grade mono-
clonal antibody, such as Cetuximab, leading to antibody-
dependent cellular cytotoxicity [63].
In parallel, attempts have also been made to render
CAR T-cell activation dependent upon the presence of
an exogenously administered compound that is able to
interact either with the CAR’s extracellular or intracellu-
lar domains. In the case of the GoCAR-T system, CAR
T-cell proliferation, activity and cytotoxicity requires
both TAA target binding as well as the presence of rimi-
ducid, which facilitates homodimerization of an indu-
cible chimeric MyD88/CD40 co-stimulatory domain
[64]. The UniCAR modular system, on the other hand,
incorporates a physiologically silent CAR that is
activated in the presence of specific targeting modules.
UniCAR T-cells may therefore be controlled more
precisely in a time- and target-dependent fashion [65].
Finally, due to the requirement for use of intensive
lymphodepleting conditioning regimens to facilitate
CAR T-cell expansion, careful patient selection is
required and currently the treatment remains suitable
only for suitably fit patients without significant co-
morbidity. Technical challenges and safety issues limit
access to this approach outside of an academic centre
experienced in the delivery of autologous haematopoietic
transplantation. Furthermore, production of CAR T-cells
is costly and time consuming due to the need to harvest,
genetically engineer and expand autologous CAR T-cells
ex vivo using cleanroom facilities. However, these issues
may be addressed by centralised large-scale manufactur-
ing, improved automation and a modular, integrated and
scalable supply chain [66, 67]. Indeed batch manufacturing
of Kite Pharma’s CD19-directed autologous CAR T-cell
product axicabtagene ciloleucel can now be performed in
just 6 days with a 2 week vein-to-vein turnaround time
[68]. Following FDA approval of its CD19-directed CAR
product tisagenlecleucel, Novartis have issued a price of
US $475,000 per patient [69], which takes into account
both the high manufacturing costs as well as the long-
term benefits to young patients who would otherwise face
costly bone marrow transplants, protracted hospital
admissions and poor survival outcomes.
Attributes of oncolytic virotherapy favourable to
combined use with CAR T-cell therapy
The activation of pathogen or tumour-targeting CD8+
T-cells is dependent upon the presence of three classical
signals: TCR engagement (signal 1), co-stimulation (signal 2)
and an inflammatory stimulus (signal 3). Signal 3 is typically
driven by cytokines such as interleukin (IL)-12 or type I
IFNs [70]. Engagement of TAAs by second or third gener-
ation CARs provide engineered T-cells with signals 1 and 2.
Whilst ex vivo activation of CAR T-cells by exposure to
CD3/CD28 antibodies may recapitulate physiological signal
3 prior to administration, it remains unclear whether this
signal remains present when T-cells enter the microenviron-
ment of solid tumours and, if so, for what duration [71]. It is
well recognised that type I IFNs can mediate anti-viral and
anti-tumour responses by promoting viral eradication and
limiting cellular proliferation, at least partly through a stimu-
latory effect on the host adaptive immune system. More spe-
cifically, type I IFNs support the proliferation, clonal
expansion, effector function and/or memory formation of
CD8+ T-cells [72]. Furthermore, IFNβ is also known to
enhance cross-priming activity of dendritic cells (DCs),
inhibit regulatory T-cell (Treg) activation and proliferation
and disrupt the tumour microvasculature [73]. It is now
recognised that OVs are capable of inducing an enhanced
type I IFN signature in the TME. In concert with secondary
enhanced DC and T-cell effector function and reduced
regulatory T-cell (Treg) and myeloid-derived suppressor cell
(MDSC)-induced immunosuppression, the immunopheno-
type of established tumours may thereby be converted from
a so-called “cold” to a “hot” state that is permissive for CAR
T-cell entry, expansion and efficacy [74].
Furthermore, studies of 4-1BB-containing second gen-
eration CARs have highlighted the potential importance
of autocrine (and likely paracrine) feedback signalling
via the secretion of IFNβ by the CAR T-cells themselves,
reinforcing the importance of type I IFN signalling for
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effector T-cell function. It has been posited that the
mechanism of type I IFN gene induction within CAR T-
cells may occur via 4-1BB signalling through its activa-
tion of TNF receptor-associated factor 2 (TRAF2) [73].
CAR T-cells with enhanced 4-1BB signalling via 4-1BB-
containing CARs or chimeric co-stimulatory receptors
(CCRs) may therefore be particularly sensitive to type I
IFN signalling within the TME and may prove particu-
larly synergistic with OVs. Due to the complex modula-
tion of effector T-cell function within the TME, signal 3
manipulation ex vivo is likely to have a profound and
crucial influence on CAR T-cell behaviour in vivo [71].
As described, OV infection and subsequent immuno-
genic cell death of cancer cells has been demonstrated
to induce systemic innate and tumour-specific adaptive
immune responses that impact upon T-cell trafficking
and effector function within the TME (Fig. 2). Release of
tumour neo-antigens and epitope spreading following
OV-induced necrosis and pyroptosis of cancer cells leads
to the recruitment of scavenging macrophages and Batf3+
dendritic cells, enhanced antigen presentation and
subsequent activation of antigen-specific CD4+ and CD8+
T-cells. These T-cells are then able to traffic into tumour
sites along chemokine gradients initiated by Batf3+ DCs in
the TME [75]. Furthermore, OV infection can promote a
permissive immunostimulatory milieu within the TME.
The latter is facilitated by OV infection of cancer cells,
leading to the release of viral pathogen associated molecu-
lar pattern signals (PAMPS). In turn, these trigger Toll-
like receptor (TLR) activation, JAK-STAT signalling, the
upregulation of viral clearance genes and local IFNα/β
release [76]. This promotes the upregulation of MHC class
I expression on cancer cells [77], which would be expected
to be synergistic with ACT using TILs or TCR-engineered
T-cells targeting specific tumour antigens such as the
melanoma-associated antigen (MAGE-A) or New York
oesophageal squamous cell carcinoma (NY-ESO) cancer-
testis antigens. Nonetheless, CAR T-cells (which function
independently of antigen presentation) would also benefit
since their recruitment into the TME remains dependent
upon chemokine signalling. Tumours with dysregulated
MHC class I expression (e.g. due to acquired or intrinsic
mutations in genes encoding β2-microglobulin or
members of the JAK-STAT-IFNγ signalling pathway) [39]
may be better targeted by CARs rather than engineered
TCRs in conjunction with OVs.
Viral-induced oncolysis also induces local release into
the extracellular environment of cellular danger associ-
ated molecular pattern signals (DAMPS) [78, 79] such as
heat shock proteins, HMGB1, ATP, calreticulin and uric
acid, as well as cytokines stimulatory of DCs and effector
T-cells, including CAR T-cells, such as type I IFNs,
tumour necrosis factor-alpha (TNFα), IFNγ, IL-12 and
IL-15. HMGB1, in particular, can enhance T-cell
activation and expansion within the TME via interaction
with the T-cell Receptor for Advanced Glycation End
Products (RAGE) [80, 81].
Furthermore, it has recently been demonstrated that
the interaction of DNA OVs with the innate immune
system’s cGAS-cGAMP-STING (Stimulator of Interferon
Genes) cytosolic DNA sensing and signalling pathway
may potentiate anti-cancer adaptive T-cell responses by
inducing type I IFN gene transcription, DC activation
and T-cell priming [82]. Type I IFN signalling is com-
monly disrupted in many different types of cancer and
an important mechanism underlying this appears to be
STING hypofunction, caused for example by inactivating
mutations within tumours. This is emerging as a puta-
tive mechanism of intrinsic or acquired resistance to a
number of immunotherapeutic modalities such as
immune checkpoint blockade. Intriguingly however,
STING-inactivated tumours have proven susceptible to
DNA OV infection due to disruption of type I IFN sig-
nalling pathways [83]. In this setting, OV infection can
induce sustained anti-cancer responses, implying that
this may occur via mechanisms independent of intact
type I IFN signalling or that OV infection may recapitu-
late IFN-regulated gene expression in these tumours.
This suggests that combination OV and CAR T-cell
therapy may be particularly efficacious in STING-
inactivated and type I IFN disrupted tumours where OV
infection may be more virulent [84] and the TME may
otherwise prove too “cold” for ACT.
Enhancement of OV-induced type I IFN-mediated T-cell
responses may be maximised by using a prime-boost
approach with the sequential application of serologically
distinct OVs [85]. In such a paradigm, it is posited that the
adaptive immune response elicited by a second OV may be
potentiated by the host immune response to the first OV,
whilst simultaneously mitigating the potential immunodo-
minance of specific viral antigens that may limit the devel-
opment of robust anti-tumoural responses. Such an
approach may provide even greater synergistic potential
when combined with ACTand CAR T-cell therapy.
The capacity of OVs to facilitate the effects of
TAA-specific ACT is illustrated in a chicken ovalbu-
min (OVA)-expressing murine melanoma model
whereby intra-tumoural injection of an adenoviral OV
could overcome resistance to the intra-peritoneal
transfer of polyclonally activated OVA-specific CD8+
T-cells [86]. Adenoviral injection led to a local
increase in pro-inflammatory cytokines, CD45+ leuko-
cytes, CD8+ lymphocytes and F4/80+ macrophages as
well as the induction of co-stimulatory signals on
CD11c+ antigen presenting cells (APCs). As a result,
T-cell activation occurred, which was accompanied by
epitope spreading (evidenced by increases in CD8+ T-
cells specific for the endogenous tumour antigens
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TRP-2 and gp100) and inhibition of tumour-induced
peripheral tolerance.
Greater synergy may be achieved by combining adaptive
anti-viral immunity with TAA-retargeted CAR T-cell ther-
apy. To explore whether the former could enhance the effi-
cacy and persistence of the latter, Epstein Barr virus (EBV)-
specific T-cells were transduced with a first generation anti-
GD2-CD3ζ CAR and compared with polyclonal redirected
CAR T-cells in a phase I neuroblastoma study. Virus-
specific CAR T-cells not only expanded more vigorously but
were found to be more persistent in the short-term, being
detectable by polymerase chain reaction (PCR) in patients
6 weeks following administration versus only 3 weeks in the
polyclonal CAR T-cell treated cohort [87]. Building upon
Fig. 2 Oncolytic virus mediated enhanced anti-tumoral immunity, including enhanced CAR T-cell recruitment and effector function. Oncolytic viral infection
of tumour cells induces immunogenic cell death (ICD) and a type I interferon response via release of PAMPs and DAMPs (such as HMGB1) acting on Toll-like
receptors and RAGE. In addition, ER stress is induced by cGAS-cGAMP-STING pathway activation, ultimately leading to the phosphorylation of IRF and the
transcription of type I interferons [13]. The local production of cytokines relevant to the activation of the innate immune system may be augmented by their
delivery using recombinant oncolytic viral vectors. Activated DCs are recruited by the local production of CCL-4. In turn, DCs secrete CXCL-9 and 10 which
attract CD8+ T-cells including CAR T-cells via CXCR3 [75]. Tumour cells with an intact interferon-sensing JAK-STAT pathway are also able to produce CXCL-9
and 10 and are induced to upregulate class I MHC [77]. Oncolysis induces neo-antigen spreading, enhanced DC function and antigen cross-presentation
leading to the activation of anti-tumoural CD8+ and CD4+ T-cells within the TME [75]. The latter interact with CAR T-cells in a supportive manner, potentially
via the expression of CD40 and other co-stimulatory molecules [141]. Oncolytic viral infection of local vascular endothelial cells may also induce the
upregulation of adhesion molecules such as ICAM and VCAM
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this approach, a further novel strategy may be to use OV
vaccination prior to peripheral blood collection, T-cell selec-
tion and transduction with CARs targeting solid tumour an-
tigens. Using this strategy researchers from Baylor College
of Medicine stimulated peripheral blood mononuclear cells
(PBMCs) obtained from patients who had received intratu-
moral JX-594, a recombinant vaccinia OV, with overlapping
peptide libraries spanning the sequences of 6 vaccinia anti-
gens. These were then transduced with a HER2-targeting
CAR product and expanded. CAR T-cells specific for these
viral antigens could secrete IFNγ in response to stimulation
with vaccinia virus (VV) peptides in intracellular cytokine
assays, suggesting that the efficacy of CAR T-cells primed to
recognise OV antigens may be enhanced when used in
conjunction with an OV vaccination schedule [88].
Potential approaches to combine oncolytic
virotherapy with CAR T-cell immunotherapy
The flexibility of recombinant genetic engineering has
led to a renaissance in the field of oncolytic virotherapy.
A plethora of modified OVs are currently undergoing
pre-clinical and clinical investigation, combining the
favoured characteristics of impaired pathogenicity / viru-
lence with enhanced oncolytic and/or immunostimula-
tory potential. Through precise editing of the viral
genome, the oncotropic nature of these agents has been
further enhanced. Similarly, such an approach may be
used to develop experimental gene therapies that deliver
a predefined therapeutic payload to the tumour, such as
one or more pro-apoptotic proteins or immunogenic co-
stimulatory surface molecules. Furthermore, the infec-
tion of tumours by oncolytic viruses has the potential to
convert cancer cells into cytokine and chemokine factor-
ies, thereby converting the TME from an immunosup-
pressive to an immunostimulatory milieu that is
permissive to T-cell entry and activation. This potential
creates opportunities to develop exciting synergies with
other immunotherapeutic modalities, including ACT
and CAR T-cell therapy. In the paragraphs that follow,
some examples of how engineered OV may be combined
with CAR T-cells are considered. A summary of these
strategies is illustrated in Fig. 3.
Delivery of cytokines that support dendritic cells/
antigen-presenting cells
The canonical example of this type of engineered OV is
T-VEC, whereby two copies of the human GM-CSF gene
have been incorporated into the HSV-1 genome at the
site of a deleted viral virulence gene (ICP34.5). Unde-
leted ICP34.5 can inhibit type I IFN activation and pro-
tein translation via blockade of the stress response
protein kinase R (PKR) pathway. It is also able to inhibit
IFNβ production by binding TANK-binding kinase 1
(TBK-1), preventing autocrine type I IFN signalling.
ICP47, a second viral virulence gene that blocks antigen
loading onto MHC class I molecules by binding to the
transporter associated with antigen processing and pres-
entation (TAP), is also deleted [76]. In the pre-clinical
testing of T-VEC, regression of both injected and un-
injected contralateral tumours was observed in immune
competent mice, accompanied by a significant improve-
ment in overall survival. These effects are mediated by
improvements in antigen presentation and T-cell prim-
ing, attributes that would not be anticipated to be
directly synergistic with CAR T-cell therapy, unless
potentiation of endogenous tumour-reactive T-cells
should prove pivotal. At a minimal level, it can be antici-
pated that CAR T-cell trafficking, activation and prolifer-
ation within the TME might all be enhanced due to the
recruitment of DCs that modulate the cytokine milieu in
favour of an adaptive immune response.
Delivery of pro-T-cell cytokines
Cytokines have been the subject of considerable research
due their pleiotropic anti-tumour effects. Following a
greater recognition and understanding of the vitally im-
portant role that the host adaptive immune system plays
in mediating OV responses, many researchers have
focused on designing recombinant OVs capable of
sculpting the cytokine milieu within the TME, thereby
tipping the balance favourably from immune suppression
to immune activation. By modulating the TME in this
way, recombinant OVs render tumours more permissive
to the entry of CAR T-cells, which may then benefit
from a nurturing environment conducive to activation
and expansion. However, care is required to ensure that
the expression of cytokine transgenes does not result in
a reduction in oncolytic activity and premature clearance
of the virotherapy from the TME. Specific cytokine
transgenes have been shown in pre-clinical models to
enhance CAR T-cell activation and proliferation by pro-
moting effector function, minimising the risk of exhaus-
tion or hypofunction and modulating T-cell plasticity
within the TME [89, 90]. Specifically, OVs have been de-
signed to produce TNFα, IL-2, IL-4, IL-12, IL-15, IL-18
and type 1 IFNs [13, 91]. Several of these cytokines
(particularly TNFα, TNF-related apoptosis-inducing
ligand (TRAIL) and type I IFNs) may also induce direct
cytotoxic effects on neighbouring uninfected cancer
cells, depending upon their susceptibility [92]. Oncolytic
HSV engineered to express a number of interleukin
genes (including IL-12 and IL-4) demonstrated improved
anti-tumour efficacy in murine glioblastoma models
[93]. Similarly, oncolytic adenovirus co-expressing IL-12
and IL-18 was found to enrich tumour-specific immun-
ity via the differentiation of T-cells [94]. Cytokine-
encoding transgenes inserted into oncolytic vaccinia
viruses include IL-1β, IL-2, IL-4, IL-6, IL-12 and IFNβ.
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Using a recombinant NDV vector, Bai et al. have demon-
strated synergistic anti-cancer efficacy with transgenes
encoding human IL-2 alongside TRAIL as well as others
encoding IL-15 [95]. Arming OVs with type I IFNs has
also been explored. When syngeneic LM2 lung tumours
grown in the flanks of immune competent mice were
injected with a VSV expressing IFNβ, researchers
observed enhanced tumour regression, prolonged sur-
vival and cure in 30% of cases. Furthermore, VSV-IFNβ
infection resulted in a decrease the numbers of tumour-
infiltrating Tregs and an increase in CD8+ T-cells [96].
Interleukin-10 has been regarded for many years as a
prototypic immunosuppressive cytokine that can inhibit
T cell-mediated anti-viral and anti-tumoural responses
[97]. However, more recently, pleiotropic effects have
been elucidated, leading to a counter-argument to this
view. Specifically, IL-10 has been shown to directly acti-
vate and expand tumour-resident CD8+ T-cells without
promoting their de novo infiltration from secondary
lymphoid organs [98]. A pegylated formulation of IL-10
is currently undergoing clinical evaluation and has dem-
onstrated potent anti-tumour activity in patients with
metastatic renal cell carcinoma [99]. A recombinant thy-
midine kinase (TK)-deleted Lister strain vaccinia OV
armed with murine IL-10 was able to elicit tumour
rejection in two murine pancreatic ductal adenocarcin-
oma (PDAC) models by prolonging the oncolytic poten-
tial of the OV and modulating innate and adaptive
immune responses [100].
Several pre-clinical studies investigating so called
“armoured” CARs or “trucks” have highlighted the
potential of CAR T-cells being further engineered to se-
crete immunostimulatory cytokines capable of promot-
ing enhanced efficacy via autocrine and paracrine effects
[101]. Whereas, the systemic administration of IL-12 can
lead to profound toxicity, expression of IL-12 by CAR-T
cells was found to be safe in a syngeneic mouse model
of CD19+ malignancies and intriguingly could obviate
the requirement for lymphodepleting pre-conditioning,
while rendering CAR-T cells resistant to Treg-mediated
Fig. 3 Recombinant oncolytic viruses with transgenes conferring direct and indirect synergism with CAR T-cell adoptive cell transfer. A large variety of
oncolytic viruses have been engineered to express transgenes capable of augmenting responses to CAR T-cell therapies applied to solid tumours. These
entities may either directly or indirectly enhance CAR T-cell efficacy by modulating their recruitment and entry within the TME, their activation and ability
to kill tumour cells, their proliferative capacity, longevity and capacity to adopt a central memory phenotype. Many of these strategies attempt to target
the immunosuppressive agents illustrated in Fig. 4 or augment many of the immunostimulatory characteristics highlighted in Fig. 2. Items enclosed in
square brackets are pharmaceutical agents that may be synergistically combined with OVs & CARs
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immunosuppression [102]. Similarly, arming CAR T-
cells with IL-2, IL-7, IL-15 or IL-21 could enhance anti-
lymphoma efficacy in an immune incompetent mouse
model [103]. Such an approach may be replicated or
enhanced by the local delivery of such cytokines to the
TME by recombinant OVs.
Thus far, only a handful of pre-clinical studies have
investigated the combination of cytokine-armed OVs
with CAR T-cells. The combination of a mesothelin-
directed second generation 4-1BB-containing CAR and
an adenovirus construct containing either IL-2 or TNFα
or both has been investigated in a preclinical mouse
model of PDAC. Oncolytic virus infection was shown to
enhance CAR T-cell efficacy in vivo and the IL-2 con-
taining adenoviral vector was associated with enhanced
T-cell numbers in mouse splenic tissue [104].
Delivery of T-cell attracting chemokines
One of the most significant challenges faced in efforts to
apply CAR T-cell therapy to solid tumours relates to
impaired CAR T-cell trafficking into the TME. Bio-
distribution studies following the systemic administra-
tion of CAR T-cells have demonstrated suboptimal
trafficking into solid tumours due to mis-localisation /
sequestration or by encountering physical or molecular
barriers to entry [38]. Immediately following their
systemic administration, CAR T-cells are prominently
detected in the lungs owing to direct trafficking through
the right ventricle and subsequent entrapment in the
alveolar microvasculature [105, 106]. This can lead to
significant toxicity in the presence of low levels of CAR-
targeting TAA and presents a hurdle to subsequent CAR
T-cell migration into the TME [61]. CAR T-cells that
manage to enter tumour draining lymph nodes or the
periphery of tumours themselves face the problem that
chemokines produced by solid tumours and cell adhe-
sion molecules expressed by endothelial cells in the
TME vasculature do not favour T-cell infiltration [57].
One method that has been employed is the direct
instillation of CAR T-cells into the TME by intra-
tumoural or regional injection [107, 108]. Whilst this
may be feasible for tumours that have spread in a purely
local fashion, disseminated metastatic disease is unlikely
to be effectively targeted in the absence of systemic CAR
T-cell delivery due to the presence of physical and/or
molecular barriers to effective T-cell migration. Further-
more, intra-tumoural injection can be both technically
challenging and risky from a safety perspective in many
solid tumours.
At the molecular level, it has been recognised that
CAR T-cell trafficking is impacted by the inefficient and
poorly coordinated expression of chemokines and cell
adhesion molecules within the TME, including the
luminal surface of tumour-associated lymphatic and
vascular endothelium, and their target receptors on the
CAR T-cells themselves. Chemokine ligand / receptor
mismatching may stem in part from the imperfect repli-
cation of physiological TCR-mediated T-cell activation
using second or third generation CARs. In recent years,
studies in mice have shed light on the vital dual role
played by Batf3+ dependent CD8α+ DCs in mediating
anti-tumour adaptive immunity. It has become clear that
murine CD8α+ (and potentially the human equivalent
CD141+) DCs are actively recruited to the TME by
tumour-associated chemokines (such as C-C motif
chemokine ligand 4 (CCL-4)) and following their arrival
are not only involved in the priming of CD8+ T-cells
during antigen cross-presentation in the afferent limb of
the anti-tumoural immune response but are also
involved in the efferent limb by responding to danger
signals via pattern recognition pathways (such as
STING) by secreting type I IFNs and IFNγ-dependent
chemokines (including C-X-C motif chemokine ligand 9
(CXCL-9) and CXCL-10) that attract primed effector
T-cells into the TME via specific chemokine receptors,
most notably CXCR3 [75]. This concept is particularly
relevant for CAR T-cell therapy which is designed to
bypass the afferent limb altogether. Using Batf3+
knock-out mice, Gajewski and colleagues showed that
type I IFN-mediated signalling in Batf3+ dependent
CD8α+ DCs was critical for the rejection of immuno-
genic tumours [109]. The exogenous delivery of the
DC-derived cytokine IL-12 can recapitulate anti-
tumour immunity associated with enhanced IFNγ
signalling within the TME [110]. The implication is that
in addition to the CD28 co-stimulatory signal normally
required for T-cell priming, CAR T-cells are likely to
require the presence of an inflamed TME with active
Batf3+ dependent CD8α+ DCs contributing to type I
IFNs and IFNγ-mediated CXCL-9/10 secretion. In the
absence of this mechanism, (e.g. in tumours with an
activated Wnt/β-catenin pathway leading to transcrip-
tional repression of CCL-4 [111]), impaired trafficking
and function of Batf3+ dependent CD8α+ DCs and a
non-inflamed tumour immunophenotype are likely
results. For these reasons, CAR T-cells are likely to
benefit from the synergistic combination with OVs
which recapitulate the required type I IFN signature, as
well as deliver the required chemokine ligands by
genetic recombination.
The importance of the C-X-C motif chemokine ligands
CXCL-9 and CXCL-10 in mediating adaptive anti-
tumour immunity is reinforced by their repeated identi-
fication in RNA-Sequencing transcriptome analysis of
tumours with an “inflamed” immunophenotype predictive
of response to immune checkpoint blockade [112, 113].
Indeed, a number of clinical studies have highlighted the
prognostic and predictive value of both CXCL-9 and
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CXCL-10 in patients receiving treatment for colorectal,
breast and high grade serous ovarian cancer [114–116].
The natural ability of OVs to enhance levels of CXCL-9
and CXCL-10 locally within the TME has been exploited
in pre-clinical studies investigating adoptive T-cell transfer
where the presence of these chemokines facilitated T-cell
migration and persistence within the TME, leading to a
significantly enhanced therapeutic effect [117]. Addition-
ally, a number of researchers have sought to arm OVs with
these chemokine ligands in an effort to exploit their ability
to modulate the TME and reverse inefficient trafficking
and local expansion of cytotoxic T-cells (as well as other
immune cells such as NK cells, macrophages & DCs)
[118, 119].
Intra-tumoural injection of a tumour-selective oncoly-
tic double-deleted vaccinia virus (vvDD) armed with the
chemokine CXCL-11 was found to enhance the recruit-
ment of tumour-specific CD8+ effector T-cells into the
TME in a murine AB12 mesothelioma model, leading to
locally elevated levels of granzyme B and reduced
expression of several suppressive molecules including
TGF-β, cyclooxygenase 2 (COX2) and CCL-22. It was
also associated with an induction of systemic anti-
tumour immunity with an increase in tumour-specific
IFNγ-producing CD8+ T-cells in the spleen and other
lymphoid organs and ultimately was associated with a
survival benefit in treated mice [118].
A vaccinia strain of OV (vvDD) designed to constitu-
tively express the chemokine CCL-5 (regulated on acti-
vation, normal T cell expressed and secreted (RANTES))
was found to increase immune cell infiltration in a
mouse colorectal tumour model leading to enhanced
therapeutic effects. Interestingly, vvCCL-5 demonstrated
a heightened capacity to persist for extended periods in
tumours in vivo [120]. Whereas in the absence of OV in-
fection enhanced tumour production of CCL-5 resulted
in Treg recruitment and progression, vvCCL-5 infection
led to CD4+ effector T-cell infiltration and a Th2 skewed
immune response. Demonstrating how combination
strategies with OVs may further modulate the TME and
enhance anti-tumoural adaptive responses, greater effi-
cacy was achieved when vvCCL-5 was combined with
DC1 vaccination – an approach known to induce high
levels of activated cytotoxic (Tc1) T-cells expressing
CCL-5 receptors – leading to further enhanced immune
cell infiltration and Th1-skewing.
The systemic or intraperitoneal administration of a
recombinant vaccinia OV (vvDD) expressing the chemo-
kine CCL-19 was found to result in enhanced anti-
tumour effects in syngeneic mouse tumour models. The
lymph node targeting receptor for CCL-19, CCR7, is
expressed in a relatively more restricted set of immune
cells (including mature DCs, T-cells and cytokine
induced killer (CIK) cells) compared to the CCL
receptors CCR1, CCR3, and CCR5 [121]. Expression of
CCL-19 did not curtail oncolytic activity and vvCCL-19
was cleared rapidly and selectively from normal tissues
suggestive of a potentially enhanced safety profile. The
researchers posited that the therapeutic activity of
vvCCL-19 could be further improved through combin-
ation with ACT of immune cells overexpressing CCR7,
and such an approach lends itself well to synergism with
engineered CAR T-cell therapy.
The use of chemokines and their receptors may be a
double-edged sword in cancer immunotherapy.
Concerns due to the potential pro-tumour effects of the
C-X-C chemokine ligands in particular have been
highlighted in a number of cancers [122]. Whilst many
CXCL-9-poor tumours have a demonstrably poorer
prognosis (presumably due to reduced adaptive anti-
cancer immunity) others appear to derive growth and
invasion signals from CXCL-9 (e.g. via over-expression
of the CXCR3 receptor [123]). For example, pre-
treatment serum CXCL-9 levels in patients with naso-
pharyngeal carcinoma (NPC) were found not only to be
significantly higher in those with higher stage disease
but predicted for poorer prognosis in terms of overall
survival and disease-free survival [124].
This disparity may be due in part to the diversity of
chemokine targets and functional differences exhibited
by individual chemokine receptor isoforms. For example,
studies have demonstrated two main sub-types of the
CXCR3 receptor: CXCR3-A and CXCR3-B, which may
be expressed in a differential fashion on the surface of
immune cells and tumour cells. A third sub-type,
CXCR3-alt, is a poorly understood variant that is gener-
ated by the alternative splicing of mRNA encoding
CXCR3-A and fails to signal in response to CXCL-9 or
CXCL-10 [125]. When expressed on tumour cells
CXCR3-A is pathogenic, interacting with CXCL-9 to
promote tumour migration and invasion via the activa-
tion of phosphatidylinostol 3-kinase (PI3K) and mitogen
activated protein kinase (MAPK) signalling pathways. By
contrast, CXCR3-B is anti-angiogenic in this context,
interacting with CXCL-9 to depress endothelial cell
proliferation and tumour angiogenesis. Expression of
CXCR3-A on T-cells fosters chemotaxis and is immuno-
genic. Furthermore, due to the overlapping targets of
chemokine ligands and their pleiotropic effects on a
variety of immune cells, there may be concerns that the
overexpression of chemokines by OVs may have unin-
tended consequences in specific tumour models. For
example, in a colorectal cancer model neuroendocrine
differentiation may induce the infiltration of tumour-
associated macrophages (TAMs) attracted by CXCL-10
and CXCL-11 leading to enhanced tumour cell prolifera-
tion and invasion [126]. CXCL-9 may also negatively
impact on the TME by attracting Tregs and inducing
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CXCR3+ B-cells to polarise immunoregulatory (M2b)
TAMs [127]. The chemokine fractalkine (CX3CL1) has
also been implicated in the invasive and metastatic
potential of several tumours including lung, ovarian and
prostate cancer. In ovarian cancer, high expression of
the fractalkine receptor CX3CR1 correlated with signifi-
cantly shorter survival in post-menopausal patients with
advanced disease [128].
Oncolytic viruses have therefore been designed to tar-
get the pro-tumour effects of specific chemokine ligand
/ receptor interactions that are believed to play a role in
tumour cell extravasation and metastasis. For example,
the systemic delivery of a vaccinia OV armed with a
CXCR4 antagonist to mice with orthotopic mammary
tumours disrupted the interaction between tumour cell
CXCR4 and CXCL-12 present in the stromal micro-
environment. This lead to tumour growth retardation, a
reduction of spontaneous metastasis, the destruction of
tumour associated vasculature and increased overall
tumour-free survival [129].
Delivery of pro-T-cell cytokines & chemokines in
combination
Nishio and colleagues have demonstrated that Ad5Δ24
(an oncolytic adenovirus armed with the chemokine
CCL-5/RANTES and the cytokine IL-15) could be used
synergistically with 3rd generation human CAR T-cells
(specific for GD2 and containing the CD28 and OX40
intracellular signalling domains) in a neuroblastoma-
bearing immune compromised NOD SCID γcnull (NSG)
mouse model. Specifically, OV infection directly acceler-
ated the caspase-dependent death pathways within
tumour cells exposed to CAR-T cells and the intra-
tumoural release of both CCL-5 and IL-15 attracted
CAR-T cells and promoted their survival within the
TME, thus increasing the overall survival of the mice
studied [130, 131]. Naturally, by using an immunodefi-
cient mouse model, any potential interplay between the
OV, CAR T-cells and inhibitory immune cells such as
Tregs, TAMs and MDSCs cannot be properly assessed.
This will require additional study using either murine
CAR T-cells in an immune competent mouse model or
by using appropriate humanised mouse models [132].
Delivery of immune co-stimulatory molecules
Oncolytic viruses have also been armed with co-
stimulatory molecules to enhance the local activation
and expansion of effector immune cells within the TME.
In studies without combination ACT, arming adenovirus
and vaccinia vectors with TNF receptor superfamily
ligands including OX40L, 4-1BBL, and GITRL led to
enhanced anti-tumour effects [133–135]. In addition,
OVs have been armed with transgenes encoding mem-
brane bound or soluble CD40 ligand (CD40L), thereby
enhancing local CD40 activation within the TME [136, 137].
Due to the variable expression of CD40 on a wide variety of
immune cells, including CD4+ helper T-cells, macrophages
and B-cells, activation of this pathway mediates anti-tumour
immunity in a pleiotropic manner [138]. For example, a
novel oncolytic adenovirus armed with trimerized
membrane-bound extracellular CD40L led to the activation
of myeloid and endothelial cells, supporting T-cell expansion
and migration into the TME. The researchers hypothesised
that CD40L-mediated gene therapy may prove to be par-
ticularly promising for the targeting of tumours with high
levels of M2 macrophages, such as PDAC [139]. Further-
more, the enhanced natural expression of CD40L on CD8+
effector memory T-cells and our emerging understanding of
the role of CD40/CD40L interactions (particularly between
CD4+ and CD8+ T-cells) in supporting an effector memory
phenotype [140, 141] suggests that the activation of this
pathway may be particularly synergistic with ACT including
CAR T-cell therapy. This approach has also been explored
in the ACT space by arming CAR T-cells with constitutively
expressed CD40L [142]. CD40L-modified T-cells demon-
strated increased proliferation and secretion of pro-
inflammatory Th1 cytokines and an ability to induce
monocyte-derived DC maturation and secretion of IL-12.
Oncolytic viruses have also been armed with B7-1
(CD80), a co-stimulatory molecule overexpressed by
mature DCs at the time of antigen cross-presentation medi-
ated effector T-cell activation. Specifically, a vaccinia virus
engineered to either express B7-1 alone or in combination
with the cell adhesion molecules ICAM-1 and lymphocyte
function-associated antigen 3 (LFA-3) (the triplet combin-
ation termed TRICOM) can provide an optimised form of
co-stimulation required by anti-tumour CD8+ T-cells and
has demonstrated efficacy and tolerability in several early-
phase clinical trials in patients with malignant melanoma
[143]. In these studies, adverse events were mild, consisting
of flu-like symptoms and local injection site reactions.
Interestingly, several patients subsequently developed auto-
immune vitiligo.
Delivery of molecules targeting immune checkpoints
The efficacy of TIL-based and other forms of ACT may
be subject to numerous inhibitory immune-checkpoint
molecules able to exert their effects at various stages of
effector T-cell activation and expansion. These include
CTLA-4, PD-1, B7-H family members and Fas ligand
[144]. Numerous additional T-cell suppressive cell
surface molecules are currently being characterised and
the complexity of immunosuppressive signalling within
the TME is further apparent when one considers the
dynamic temporospatial expression of these molecules.
Many of the effects seen in TIL therapy are applicable to
CAR T-cell therapy. For example, both TCR-engineered
and CAR-T cells routinely express PD-1 and are
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susceptible to PD-L1/PD-L2-mediated suppression [145,
146]. Furthermore, CAR T-cell hypofunction in the TME
has been shown to be associated with the up-regulation
of intrinsic T-cell inhibitory enzymes, including diacyl-
glycerol kinase (DGK) and SHP-1, and the expression of
cell-surface inhibitory receptors including PD-1, LAG3,
TIM3 and 2B4 [147].
Whilst it would be anticipated that CAR T-cell therapy
could be synergistically enhanced if used in combination
with licensed immune checkpoint inhibitors (such as
mAbs targeting PD-1, PD-L1 or CTLA-4), recombinant
OVs armed with these agents may replicate this function
in a more targeted, safe and nuanced manner as well as
providing a plethora of other pro-inflammatory signals
conducive to innate and adaptive anti-tumour responses.
In keeping with this, a recombinant adenoviral OV has
been armed with a full length IgG2 mAb targeting
human CTLA-4 [148]. Murine PD-1 has been success-
fully targeted with a Western Reserve (WR) oncolytic
vaccinia virus armed with either a full-length hamster
monoclonal IgG antibody, a fragment antigen-binding
(Fab) fragment or a single-chain variable fragment (scFv)
[149]. Intra-tumoural injection of these OVs induced a
very significant infiltration of immune cells into the
TME of melanomas and fibrosarcomas in immune com-
petent mice. In the latter, OVs armed with whole anti-
body or scFv mediated superior anti-tumour effects
compared to the unarmed virus. Furthermore, due to
their ability to induce epitope spreading, OVs armed
with anti-PD-1 molecules may also actively limit ac-
quired resistance to immune checkpoint blockade by
broadening neoantigen-directed T-cell responses.
In a similar fashion, OVs armed with soluble PD-1
traps or secreted antibodies/scFvs targeting other cell
surface immune checkpoints such as TIM3, LAG3,
VISTA, BTLA, CD200R, KLRG-1 and 2B4 would be
expected to function synergistically with CAR T-cell
therapy. Several similar strategies are also being
employed in the design of novel CAR T-cells that have
been engineered, for example, to secrete PD-L1 anti-
bodies [150] or co-express a cell surface PD-1 dominant
negative receptor [151]. One may also envisage arming
OVs with intrabodies (intracellular antibodies), inhibi-
tory short hairpin RNAs (shRNAs) or ribozyme switches
targeting cancer cell surface co-inhibitory molecules such
as PD-L1, B7-H, CD47 (inhibiting phagocytosis by macro-
phages) or other inhibitory ligands.
Delivery of molecules targeting immunosuppressive cells
A very significant obstacle to effective CAR T-cell ther-
apy in solid malignancy relates to the immunosuppres-
sive signalling mediated by a variety of immune cells
within the TME. The most commonly encountered
players in this milieu include Tregs, TAMs, MDSCs,
fibroblasts and endothelial cells [57]. This challenging
environment is illustrated in Fig. 4, where several
immunosuppressive environmental factors sustain
effector T-cell exclusion and impaired function within
the TME. A great deal of work has been conducted
exploring how OVs can negate TME immunosuppres-
sion and reverse signalling that is non-permissive to
CD8+ T-cell expansion and effector function. These
strategies would be expected to combine synergistically
with ACT and CAR T-cell therapy.
Transforming Growth Factor-β and Tregs are major
contributors to the formation of immunosuppressive
networks within the TME. The former suppresses the
activation, maturation, and differentiation of immune
cells such as effector T-cells, NK cells, and DCs [23] and
is also a vital enabler of the maintenance and prolifera-
tion of Tregs, which further enhance local immunosup-
pression by autocrine secretion of TGF-β and IL-10
[152]. Decorin is a prototypic member of the small
leucine-rich proteoglycan family and blocks the inter-
action between TGF-β and its receptor. In a murine
orthotopic mammary tumour model, infection with a
recombinant adenoviral OV armed with IL-12 and
decorin limited the number of Tregs in draining lymph
nodes and tumour tissues while promoting enhanced
intra-tumoural infiltration of CD8+ T-cells [153].
The complexity of cellular interaction within the TME
may reveal unforeseen factors with regards to OV infec-
tion. Tumour secretion of TGF-β is known to enhance
the transition of normal fibroblasts to a cancer-
associated fibroblast (CAF) phenotype, via epigenetic
regulation [154]. In turn, CAFs can induce epithelial-
mesenchymal transition (EMT) of tumour cells through
paracrine TGF-β signalling [155]. Cancer-associated
fibroblasts have also been found to be more susceptible
to infection by a variety of OVs and may thus act as a
decoy reservoir of infection [156]. However, the infection
of CAFs was found to lead to enhanced secretion of
fibroblast growth factor 2 (FGF2) leading in turn to im-
paired evasion of tumour cells to OV infection [157].
Furthermore, a Maraba MG1 virus encoding human
FGF2 was found to have enhanced oncolytic potential in
tumours but failed to replicate in or kill normal cells.
Glucocorticoid-induced TNFR-related protein (GITR)
is a cell surface receptor that is constitutively expressed
at high levels on Foxp3+ Tregs and at low levels on naïve
and memory T-cells [158]. Upregulation of GITR occurs
rapidly in effector T-cells via canonical NFκB signalling
following activation. Binding of cognate ligand (GITRL)
promotes proliferation, cytokine production [159], resist-
ance to Treg suppression [160] and inhibition of Treg
suppressive function [161]. Using in vivo experimental
models, the administration of a GITR agonist antibody
is associated with reduction of intra-tumoural Treg
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accumulation and potentiation of anti-tumour CD8+
effector T cell function, leading to enhanced anti-
tumour effects [162]. It is to be expected that recombin-
ant OVs armed with membrane-bound or soluble
GITRL may enhance effector T-cell function by abrogat-
ing Treg-mediated immunosuppression. In support of
this, intra-tumoural injection of melanomas with an
adenovirus expressing either soluble or full length
GITRL led to increased local CD4+ and CD8+ T-cell
infiltration compared to controls [135]. Furthermore,
tumours receiving soluble rather than full length GITRL
exhibited greater growth retardation.
Conditioning regimens have also been utilised to
deplete Tregs prior to OV administration and overlap
Fig. 4 Immunosuppressive influences on CAR-T cell effector function within the tumour microenvironment. A large number of molecular and cellular players
have been implicated in the development of an immunosuppressive milieu non-conducive to anti-tumoural T-cell recruitment, trafficking and effector
function. Successful implementation of CAR T-cell therapy for solid tumours will necessitate the targeting of many of these players. Key environmental factors
include: intra-tumoural hypoxia (exacerbated by VEGF); low pH (in part due to tumour cell lactic acid production); deficiencies of critical or semi-critical amino
acids (e.g. tryptophan via IDO1/TDO or arginine via arginase 1 respectively); high levels of ATP and adenosine; increased COX activity and production of PGE2;
high levels of immunosuppressive cytokines such as TGFβ and IL-10; upregulation of immune checkpoints on tumour cells and immune cells
(particularly PD-L1, LAG-3 and TIM-3); the presence of a relatively impenetrable ECM; and high levels of reactive oxygen and nitrogen species
[58]. Many of these factors either directly limit CAR T-cell function or augment the differentiation, recruitment, proliferation and immunosuppressive
function of local immune cells within the TME such as Tregs, MDSCs, TAMs and CAFs [14]. DCs are also rendered dysfunctional and whilst CARs can
target TAAs or TSAs independent of DC cross-priming, CAR T-cell trafficking and effector function are likely to be negatively impacted by DC
dysfunction and loss of CXCL-9/10 chemokine signalling particularly [75]. In addition, high levels of VEGF and hypoxia may limit CAR T-cell entry by
causing local disruption of the vascular endothelium and the downregulation of cell surface adhesion molecules [223] to aid CAR T-cell rolling and
intra-tumoural migration
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with strategies used in ACT and CAR T-cell therapy. For
example, utilisation of a non-toxic dose of IL-2 resulted in
mild vascular leak syndrome which, accentuated by the
depletion of Tregs, facilitated the localization of a system-
ically delivered vesicular stomatitis virus (VSV) OV in
established tumours in immune-competent mice [163].
Use of the monoclonal antibody (mAb) ipilimumab to
target the CTLA-4 pathway has been a standard of care in
patients with advanced malignant melanoma for a number
of years. Ipilimumab is known to disrupt effector T-cell
expansion by binding to cell surface CTLA-4, which is
upregulated on the T-cell surface following antigen cross-
presentation by DCs. Moreover, a number of studies have
highlighted the importance of Treg inhibition in contribut-
ing to ipilimumab’s clinical efficacy [164]. Regulatory T-cells
constitutively express high levels of CTLA-4 which can bind
directly to B7 cell surface molecules found on both DCs and
activated T-cells, inducing immunosuppressive circuits and
tolerance. The induction of potent and non-specific auto-
immune toxicity following systemic delivery of ipilimumab
has led to safety concerns. This is particularly the case when
ipilimumab is combined with anti-PD-1 immune checkpoint
inhibitors and may in part be the result of systemic rather
than local inhibition of Tregs. An oncolytic adenovirus
(Ad5/3-Δ24aCTLA4) has been armed with a complete
human IgG2 subtype mAb specific for CTLA-4 and was
tested in vitro, in vivo and in PBMCs of normal donors and
patients with advanced solid tumours. Infection with this
virus induced high local levels of anti-CTLA-4 mAb in the
TME compared to blood [148]. However, the impact on
host Tregs could not be assessed in a murine model when
targeting human CTLA-4.
Finally, OVs may be armed with secreted inhibitors of
Treg-attracting chemokine ligands (such as CCL-1,
CCL-17 and CCL-22 [165]), Treg chemokine receptors
(such as CCR4 and CCR8), or Treg-derived suppressive
cytokines other than TGF-β (such as IL-10 and IL-35).
Recombinant OV-mediated disruption of the neuropilin
1 / semaphorin signalling pathway may also constitute a
novel strategy for inducing Treg depletion and reduced
suppressive function within the TME [166].
Tumours rich in MDSCs are poorly accessible to effector
T-cells and generally respond poorly to immunotherapy
with checkpoint blockade. The immunophenotype of such
tumours have been characterised using gene signatures and
they are often termed “mesenchymal” e.g. consensus
molecular subtype 4 (CMS4) in colorectal cancer [167].
Few strategies are currently available in the clinic to target
such tumours. However, an oncolytic vaccinia virus
expressing the PGE2-inactivating enzyme 15-prostaglandin
dehydrogenase (HPGD) was found to significantly reduce
both PGE2 and the number of infiltrating granulocyte-like
(G)-MDSCs within the TME via a reduction in local
CXCL-12 levels [25]. The importance of targeting
mechanisms of immune suppression as well as enhancing
immune activation is illustrated in the same model where
immune-enhanced vaccinia strains (including WR.TK-
mGM-CSF) were unable to elicit effective anti-tumour
adaptive immunity in tumours with high baseline levels of
G-MDSCs.
Immunotherapy using a GD2-redirected 3rd generation
CD28 OX40 CD3ζ CAR in a mouse xenograft neuroblast-
oma model was found to be augmented using all-trans ret-
inoic acid (ATRA) which was able to eradicate monocytic
MDSCs and diminish the suppressive capacity of G-MDSCs
which otherwise limited CAR T-cell activity in the TME
[168]. Such an effect is likely to be mediated by ATRA’s
known ability to impair the proliferation of CD34+ precursor
cells and curtail MDSC myelopoiesis [169]. While ATRA
has been explored as an adjuvant therapy in conjunction
with a suicide gene carrying adenoviral vector (Ad-TK/
GCV) [170] its potential to enhance the synergistic combin-
ation of OVs with cellular therapies remains to be explored.
Likewise, OVs armed with enzymes and proteins required
for ATRA synthesis such as RDH10, RALDH2 and CRABP2
remain to be developed.
Delivery of molecules enhancing T-cell and tumour cell
engagement
Recombinant OVs have been designed to enhance the
engagement of effector T-cells with tumour cells by
being armed with bispecific adapter proteins [171, 172].
Alternatively, these molecules have been utilised as
accessory pharmacotherapies to enhance the adaptive
immune response generated by oncolytic virotherapy
[173]. These molecules termed bispecific T-cell engagers
(BiTEs) have already entered into clinical practice
following the approval of Blinatumomab, a BiTE linking
anti-CD3 with anti-CD19, for the treatment of
Philadelphia chromosome-negative relapsed or refrac-
tory B-cell precursor ALL [174]. Haas and colleagues
have developed a recombinant bispecific single-chain
antibody with one arm specific for NDV-expressing
hemagglutinin-neuraminidase (HN) molecules and the
other arm specific for the CD3 or the CD28 antigen on
human T-cells [173]. The cross-linking of NDV-infected
tumour cells with effector T-cells led to enhanced
polyclonal T-cell-mediated cytotoxicity at nanomolar
concentrations in vitro. Anti-tumour efficacy was further
enhanced when PBMCs or purified T-cells were co-
incubated with this agent for 3 days and then serially
transferred to new tumour cell monolayers.
Wang et al. have developed a novel T-cell engager
armed vaccinia virus (TEA-VV) that, following the infec-
tion of tumour cells, results in the secretion of potent
bispecific antibodies binding both T-cell-associated CD3
and the tumour-associated cell surface antigen EphA2
[172]. The resulting EphA2-TEA-VV displayed
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significantly enhanced efficacy by inducing the bystander
killing of tumour cells not yet infected with virus.
Furthermore, the researchers investigated a potentially
synergistic paradigm with CAR T-cell therapy by
demonstrating that EphA2-TEA-VV could replicate in
HER2-redirected CAR-T cells. Furthermore, the pres-
ence of Eph2-TEA-VV in co-culture assays with CAR T-
cells could strongly enhance the killing of HER2+EphA2
+ A549 tumour cells. Aside from the independent anti-
tumour effects of HER2-redirected CAR-T cells recog-
nising and lysing HER2 positive tumour cells and the
oncolytic potential of the vaccinia virus, the researchers
highlighted the synergistic potential of the locally
secreted bi-specific antibody expressed by EphA2-TEA-VV
directing T-cells to recognise and kill EphA2-expressing
tumour cells, overcoming tumour heterogeneity. Such a
strategy may circumvent the need to co-express CARs
targeting more than one TAA and may exploit the multifari-
ous mechanisms by which OV-infection can render the
TME more permissive to CAR T-cell entry and activation.
In a similar vein, one may envision the design of a
recombinant OV capable of inducing the local secretion of
small protein-linked Fabs or scFvs targeting specific TAAs
e.g. HER2 or PSMA. A cognate CAR may then be
designed to target a homologous protein moiety within
the Fab in a similar fashion to the “uniCAR” system [65].
These Fabs could then act as locally delivered bridging
molecules for “off the shelf” CAR T-cell therapy.
Delivery of molecules targeting immunosuppressive
metabolic pathways within the tumour microenvironment
Both OV infectivity and CAR T-cell function may be
compromised by a hostile metabolic milieu in the TME
(illustrated in Fig. 4). Negative factors that impact on both
include tumour hypoxia, oxidative stress, tryptophan deple-
tion due to high IFNγ-induced indoleamine 2,3-dioxygen-
ase 1 (IDO1) levels and low pH [58]. Factors impacting
predominantly upon CAR T-cell efficacy include a TME
rich in inhibitory prostaglandins (e.g. PGE2) or adenosine
and one where electrolyte imbalances many impact upon
transmembrane ion shifts vital for T-cell effector function.
Recombinant OVs may be able to reverse this immunosup-
pressive TME by targeting specific metabolic pathways
inhibitory to T-cell effector function. Many of these
strategies have not yet been investigated in experimental
paradigms with CAR T-cell therapy.
The COX2 / PGE2 pathway has been associated with
attracting and maintaining the suppressive phenotype of
MDSCs within the TME [175]. PGE2 is increasingly
recognised as a key mediator of resistance to a variety of
immunotherapies reliant upon T-cell function, including
immune checkpoint blockade [176]. In addition to the
aforementioned oncolytic vaccinia OV expressing HPGD
(WR.TK-HPGD+), an oncolytic HSV-1 armed with
HPGD was found to mitigate immunosuppression
mediated by PGE2 and exhibited anti-tumour effects in
an ectopic primary and metastatic breast cancer model
in mice [177].
Indoleamine 2,3-dioxygenase 1/2 (IDO1/2) and the
closely related tryptophan 2,3-dioxygenase (TDO) repre-
sent the first enzymatic step in the catalysis of the amino
acid L-tryptophan into N-formyl-L-kynurenine [178].
The dual impact of enhanced IDO/TDO activity on
decreasing tryptophan and increasing kynurenine leads
to a number of immunosuppressive effects, including
reduced T-cell activation and proliferation [179],
reduced TCR signalling [180] and enhanced Treg func-
tion [181]. Whilst there are no reported recombinant
OVs armed with IDO pathway inhibitors, in human gli-
oma cells infected with either a wild-type oncolytic HSV
strain (KOS) or one edited to remove a viral virulence
gene (ICP0) designed to counteract the normal IFNγ
response (JD05), IFNγ-induced IDO production was
found to be almost completely abrogated [182]. Vector-
induced IDO downregulation may have potential for
synergistic combinatorial use with a whole host of immu-
notherapeutic modalities including CAR T-cell therapy.
Adenosine is synthesized from adenosine monophosphate
(AMP) by the ectoenzyme CD73 and exhibits pluripotent
immunosuppressive effects in the TME, including the
impairment of NK and CD8+ T-cell cytotoxic effector func-
tion and a polarizing effect on myeloid cells to differentiate
into immunosuppressive phenotypes such as M2 macro-
phages and DCs [183]. Small molecule inhibitors of CD73
and A2AR are in clinical development [184] but thus far, no
published data describes a recombinant OV designed to
circumvent this pathway. A recently reported study has
demonstrated a profound increase in CAR T-cell efficacy
following genetic (shRNA) or pharmacological inhibition of
A2AR, particularly in combination with PD-1 blockade
[185]. Furthermore, CAR T-cells specifically engineered to
mitigate the immunosuppressive effect of enhanced adeno-
sine levels in the TME shall be described later in this review.
Hypoxia has been found to reduce the replication of
OVs in cancer cells by mediating a downregulation of
viral protein expression [186]. However, this is not
universal. Newcastle disease virus, for example, exhibits
increased oncolytic activity in hypoxic cancer cells and
can diminish hypoxia-induced HIF-1α accumulation, a
pro-survival pathway that is upregulated in a number of
tumours [187]. As such, it may represent a good partner
for cellular therapies targeting hypoxic solid tumours.
The lower pH found in many tumours has also been
addressed by the development of a pH-sensitive and bio-
reducible polymer (PPCBA)-coated oncolytic adenovirus
(Ad-PPCBA). This adenoviral derivative was able to not
only infect cancer cells at the low pH found in hypoxic
tumours but was able to circumvent the requirement for
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viral entry via the coxsackie and adenovirus receptor
(CAR) and infect cells via micropinocytosis [188].
Delivery of pro-apoptotic or cytotoxic molecules
A large number of “suicide” transgenes have been ex-
plored in recombinant OVs, particularly at a time when
researchers placed greater import on oncolytic potential
rather than immunogenicity. Whilst the latter has now
emerged at the forefront of OV development, it remains
linked to OV-induced cell death triggering the release of
neo-antigens that can engender long-lasting adaptive
immune responses. Oncolysis is in itself capable of caus-
ing tumour regression in vivo and its importance in
immune competent hosts is likely to be enhanced by the
optimisation of OV treatment schedules as well as tech-
niques to limit OV neutralisation by the host immune
system. Due to the complex interplay between OV infec-
tion and immune clearance it is likely that the insertion
of gene switches providing regulatory temporal control
of oncolysis may prove particularly efficacious.
Enhanced oncolytic potential is therefore be expected to
have broad synergism with CAR T-cell mediated cytotox-
icity. Novel OV constructs have incorporated numerous
pro-apoptotic molecules including TRAIL [189], TNFα
[190], apoptin [26] and artificial death receptor ligand fu-
sion molecules (e.g. FasL-HER2) [191]. Other suicide
transgenes have encoded bacterial cytosine deaminase
(CD) which is able to convert 5-fluorocytosine into the
cytotoxic molecule 5-fluorouracil (5-FU) [192]; and
adenovirus death protein (ADP), a nuclear membrane
glycoprotein required for efficient adenoviral cell lysis,
which can induce enhanced oncolysis if overexpressed
following insertion into the adenoviral E3 locus [193].
Spatial control over apoptotic signalling may be
achieved using host tissue-enriched or tissue-specific
promoters capable of preferentially expressing suicide
genes within cancer cells. One example is a mutant
adenovirus (Ad-OC-HSV-TK) designed to target bone
tumours. In this construct, the HSV-1 TK gene is driven
by the osteocalcin promoter. Following exposure to
thymidine analogues (such as ganciclovir), osteosarcoma
cells infected by the OV undergo DNA synthesis arrest
leading to cell death [194].
Cationic antimicrobial peptides (CMPs), small
molecules capable of disrupting lipid membranes due to
cationic and amphipathic properties, have been utilised
in recombinant OVs due to their tumouricidal and im-
mune modulatory effects. Bovine lactoferricin, a CMP
isolated from cow’s milk following acid-pepsin hydrolysis
of lactoferrin, has demonstrated potent cytotoxic effects
against a number of murine and human cancer cell lines
in vitro and in vivo [195]. A chemically modified peptide
form of bovine lactoferricin known as LTX-315 was
shown to induce the release of DAMPS associated with
immunogenic cell death [196]. A recombinant Lister
strain vaccinia OV armed with both lactaptin, a pro-
aopototic proteolytic fragment of kappa-casein found in
human breast milk, and GM-CSF was found to demon-
strate enhanced tumouricidal function in vitro compared
to a GM-CSF-armed control. Furthermore, the dual
armed OV was able to induce significantly delayed
tumour growth in both a chemosensitive and chemore-
sistant mouse tumour model [197].
Oncolytic viruses have also been combined with other
pro-apoptotic molecules, and these synergistic combina-
tions may be further exploited by combination with
cellular therapies such as CAR T-cell therapy. In particu-
lar, second mitochondria-derived activator of caspases
(Smac) mimetic compounds (SMCs), which, by counter-
ing inhibitor of apoptosis proteins (IAP) are able to
sensitise tumour cells to apoptotic signalling induced by
inflammatory cytokines, have been used in combination
with OVs to induce potent bystander tumour cell death
[198]. This strategy may be particularly effective in
“non-inflamed” tumours and may be further enhanced
by the arming of OVs with pro-apoptotic cytokines such
as type I IFNs, TNFα or TRAIL.
Delivery of molecules capable of structurally altering the
tumour microenvironment
Oncolytic virus infection may induce structural changes
within the TME conducive to CAR T-cell entry and
mobilisation. The dense fibrotic stroma present in a
number of solid tumours enriched with MDSCs and
fibroblasts constitutes a formidable physical barrier to
both OV infection and T-cell entry [57]. Outside of the
OV and ACT field, enzymes such as heparanase and
hyaluronidase which target the fibroblast-derived extra-
cellular matrix have been investigated in early phase
clinical trials. The parenteral administration of a pegy-
lated recombinant human hyaluronidase (pegPH20) can
dramatically alter the structure of desmoplastic tumours
such as PDAC. Mid-stage reporting of the phase II
HALO-202 trial reports a significant progression free
survival advantage (from 5.2 to 9.2 months) using
pegPH20 in combination with nab-Paclitaxel and Gem-
citabine in patients with advanced PDAC and high levels
of hyaluronan [199]. Collagen in the ECM may be
degraded by co-injection with a bacterial collagenase
thus improving the spread and efficacy of an oncolytic
herpes simplex virus [200]. Oncolytic viruses have there-
fore been engineered to express ECM-degrading
enzymes such as hyaluronidase, leading to increased OV
dissemination within the tumour and therapeutic activity
in a melanoma xenograft model [201]. An oncolytic
adenovirus expressing the collagenase matrix metallo-
proteinase 9 (MMP)-9 has also demonstrated improved
viral spread in human pancreatic and lung cancer
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xenograft models [202]. Such an approach would appear
to be more attractive than engineering CAR T-cells to
express such enzymes given that the latter would be
anticipated to encounter the same problem of TME-
entry that their payload was designed to circumvent.
Oncolytic viruses may also induce direct or indirect
effects on the tumour microvasculature such as
enhanced vascular permeability that are expected to be
synergistic with CAR T-cell therapy. Indeed, several OVs
including VSV and HSV have been demonstrated to
preferentially infect tumour-associated endothelial cells
[203]. A number of systemically administered vaccinia
strains are not only endothelial cell-tropic but harbour
the capability to directly modulating the vasculature of
tumours to exert an anti-tumour effect. Oncolytic
viruses may be armed with anti-angiogenic molecules
such as vascular endothelial growth factor (VEGF)/
VEGF receptor inhibitors (e.g. ONYX-015), anti-
angiogenic cytokines e.g. IL-12, IL-18 or IL-24 or small
interfering ribonucleic acids (siRNAs) targeting the pro-
angiogenic cytokine IL-8. Furthermore, OVs have been
armed with anti-angiogenic chemokines such as platelet
factor 4 or the angiostatic C-X-C motif chemokines
CXCL-10 and CXCL-12. A plethora of endogenous anti-
angiogenic molecules have also been explored in recom-
binant OVs including endostatin, angiostatin, vasculosta-
tin, plasminogen kringle 5, canstastin and the fibroblast
growth factor receptor (FGFR) [204]. As yet, these anti-
angiogenic OVs have not been explored in combination
with ACT and it is unclear whether this approach may
be replicated by the systemic delivery of anti-angiogenic
agents already licensed for the treatment of solid
tumours such as the anti-VEGFA mAb bevacizumab or
the anti-VEGFR2 mAb, ramucirumab.
Dual modification strategies involving both CAR T-cells
and oncolytic viruses
A multitude of approaches designed to enhance CAR T-cell
efficacy are undergoing evaluation. Enhanced tumour speci-
ficity and spatiotemporal control may be achieved with the
use of co-expressed inhibitory iCARs [205] or logic-gated
control circuits [206]. Inhibitory checkpoints in the TME
can be harnessed to provide positive signals, for example
using “switch CARs” [207] or through co-expression of
secreting small molecule traps or antibodies [150]. Durabil-
ity of T-cell function can be enhanced by targeting respira-
tory pathways within the CAR T-cells themselves. Whilst
all of these approaches would all be expected to enhance
CAR T-cell synergism with oncolytic virotherapy, they
represent indirect means to achieve this.
One method, however, that may foster direct synergism
involves chemokine receptor and ligand matching. Newick
et al. engineered mesothelin-redirected CAR T-cells to
express a “regulatory subunit I anchoring disruptor”
(RIAD) that blocks the association of protein kinase A
(PKA) with the transmembrane molecule ezrin, thus pre-
venting adenosine or PGE2-mediated TCR inactivation.
By this means, CAR T-cell trafficking and anti-tumour
efficacy could be augmented. These CAR T-cells demon-
strated increased TCR signalling, enhanced cytokine pro-
duction and more robust effector function. However, their
increased efficacy in vivo was also found to be dependent
upon secondary overexpression of CXCR3, the main
receptor for the IFNγ-dependent chemokine ligands
CXCL-9 and CXCL-10 found at elevated levels the TME
of inflamed tumours [208]. CXCR3 upregulation occurs
rapidly in T-cells following DC-induced activation and
prior to proliferation in an antigen-specific manner. Since
CAR T-cell function bypasses the need for DC engage-
ment and cells are activated ex vivo, CXCR3 upregulation
may be not be sustained to facilitate migration to the
TME. The forced upregulation of CXCR3 is therefore par-
ticularly pertinent to CAR T-cell therapy over other forms
of ACT. The approach is also attractive as it may allow
anti-tumour responses to access a CXCR3-chemokine
dependent amplification loop whereby local CXCR3 lig-
and expression in the TME (potentially induced by non-
specific OV-mediated IFNγ release or by recombinant
engineering) promotes the additional recruitment of
CXCR3+ CAR T-cells, which in turn secrete IFNγ locally
activating the transcription factor STAT1 in TME resident
cells further amplifying the infiltration of CAR T-cells
[209]. In CAR T-cell therapy, this feedback loop may pro-
vide a means of replicating the “inflamed” immunopheno-
type of tumours enriched in IFNγ due to DC-mediated
antigen presentation to CD4+ and CD8+ T-cells.
With the aim of improving mesothelin-directed CAR
(mesoCAR) T-cell therapy for malignant pleural meso-
thelioma (MPM), investigators sought to match-up
tumour-specific chemokine secretion with the forced
expression of a matching chemokine receptor. Of 20
chemokines and cytokines examined from the super-
natant of 11 human MPM cell-lines, CCL2 stood out as
one of the most highly and uniformly expressed.
MesoCAR T-cells engineered to co-express the CCL-2
receptor CCR2b exhibited significantly enhanced
intra-tumoural trafficking and anti-tumour effects
[210]. Such an approach may be expected to function
synergistically with an MPM-tropic recombinant OV
armed with CCL2.
In a non-CAR model of ACT, enhanced chemokine
ligand / receptor matching was demonstrated using
adoptively transferred T-cells engineered to express
CX3CR1 (the fractalkine receptor), leading to enhanced
homing towards CX3CL1-producing tumours and im-
proved efficacy in an immunodeficient mouse xenograft
model [211]. These studies provide further evidence that
correcting the chemokine gradient between the systemic
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circulation and the tumour is likely to be an essential
requirement for effective ACT including CAR T-cell
therapy. Suggested strategies may therefore include OV-
mediated overexpression of CCL-5 matched with CAR
T-cell overexpression of CCR1, CCR3 or CCR5; matched
overexpression of CXCL-11 and CXCR3; or CCL-19 and
CCR7; and CX3CL1 and CX3CR1. Although to a certain
extent, this is provided by non-chemokine receptor-
engineered CAR T-cells which retain CCR1, CCR3, and
CCR5 expression following ex vivo expansion, additional
modification of the CAR T-cell may facilitate more ro-
bust homing to a specific TME. Such an approach may
be optimally tailored by choosing a chemokine ligand
and receptor matching pair that overlaps with physio-
logical chemokine ligand expression in specific tumours
e.g. using CX3CL1/CX3CR1 matching in ovarian cancer
[128] or CCL-19/CCR7 matching in breast cancer [212].
One safety concern regarding the forced upregulation of
baseline chemokine receptors in ACT is the risk of indu-
cing autoimmunity. Both CXCR3+ and CCR5+ T-cells
have been found to associate with inflammatory lesions in
a number of autoimmune diseases, e.g. colonic mucosa in
ulcerative colitis and myelinated neural tissue in multiple
sclerosis [213]. The use of CAR T-cells which can function
independently of antigen cross-presentation may be far
less prone to this than polyclonal TCR TIL-based therapy.
Strategies designed to render TCR-signalling non-
functional or delete the TCR complex itself are likely to
mitigate this risk.
An alternative matching strategy may involve the
matched overexpression of co-stimulatory ligands and
receptors by OV-infected cancer cells and CAR T-cells
respectively. For example, OVs encoding B7.1 and/or
B7.2 may enhance the functionality of CAR T-cells that
express endogenous CD28. Similarly, OV encoding
CD40, CD40L, 4-1BBL or OX40L may be utilised syner-
gistically with CAR T-cells that express the appropriate
counter-receptor.
Delivery of oncolytic viruses by CAR T-cells or tumour-
infiltrating lymphocytes
The systemic delivery of OVs has been compromised by
technical and clinical challenges. These range from the
induction of severe cytokine-mediated toxicity (e.g. sys-
temic adenoviral OV administration) to impaired infect-
ivity and persistence due to host immune evasion. A
number of groups have highlighted the potential of
cellular therapies (including CAR T-cells) to deliver OVs
more effectively to their target in vivo [214–216]. Such
an approach potentially circumvents many of the chal-
lenges with systemic OV delivery and poor tumour tar-
geting and infectivity. The repeated administration of
OVs induce antibody and complement-induced immune
evasion and viral clearance. The effect is amplified in
previously immunized individuals. Whilst various condi-
tioning strategies have been employed to mitigate this ef-
fect e.g. utilising cytotoxic agents or targeted therapies
such as cyclophosphamide or rituximab to deplete B-cells
[31] or complement inhibition (e.g. in preclinical models
using compstatin, a 13 amino acid cyclic peptide able to
bind to human C3 and C3b [30] or by using sub-lethal
dose cobra venom factor [217]), the carriage of OVs by
cellular products such as CAR T-cells may shield them
from the host immune system whilst inducing a synergis-
tic bystander effect in the TME. However, whilst this
approach appears elegant, OV-infected CAR T-cells are
still expected to encounter the same barriers to T-cell
entry seen in many solid tumour models. Alternative
approaches designed to overcomes immune suppression
include the selection of specific OV strains intrinsically
resistant to antibody or complement-mediated clearance
(e.g. extracellular enveloped virus (EEV)-high VVs [218])
or by introducing novel structural changes to the viral
coating itself e.g. with multi-layer ionic polymers [219].
Conclusions, outstanding questions and potential
future strategies
The number of potential strategies to fruitfully combine
OV and CAR T-cell immunotherapy are legion. Due to
the complexity of OV and immune cell inter-
relationships, optimal synergy between these two immu-
notherapeutic modalities is unlikely to benefit from the
optimisation of each arm independently. Oncolytic virus
infection, for example, may be forestalled by the injudi-
cious adaptation of CAR T-cells able to elicit potent
anti-viral effects. Likewise, CAR T-cell function is
unlikely to be enhanced in a synergistic fashion by using
an OV with improved oncolytic function mediated by
apoptotic, rather than immunogenic cell death. Instead,
a more considered systems-based approach is likely to
be more profitable when combining OVs with solid
tumour-redirected CAR T-cells. Considerable work is
required to counteract the immunosuppressive milieu
within many solid tumours, which is both non-
permissive to CAR T-cell entry and non-conducive to
CAR T-cell expansion and anti-tumour effector function.
It remains to be seen whether sufficiently potent and
selective OVs can be designed to negate these barriers to
effective CAR T-cell therapy in future clinical trials.
Given the plethora of OV families and strains currently
under investigation, it is unclear which OV subtypes will
prove most conducive to synergistic combination with
individual CAR T-cell products. In view of the great
diversity of tumour-tropism, specificity, transgene car-
riage capacity and impact upon host innate and adaptive
immune responses it is likely that individual OVs will be
selected for their particular attributes and ability to
counteract the specific problems encountered by each
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specific CAR T-cell strategy. With the FDA’s recent
approval of tisagenlecleucel for children and young adults
with ALL, it is intriguing to consider whether CAR and
OV synergism could be evaluated in haematological malig-
nancy, thus potentially accelerating proof of principle.
Certainly, a number of OVs (such as parvovirus and
NDV) have been evaluated in preclinical models of leu-
kaemia, lymphoma and myeloma [220, 221]. The local
induction of innate immunity following OV infection
coupled with the potential to enhance CAR T-cell homing
and effector function by inserting specific transgenes into
the OV genome may be expected to yield improved results
with CD19-directed CAR T-cells. However, the consider-
able single agent efficacy of the latter in this setting would
suggest that the bar to demonstrating effective synergism
may be significantly higher than in solid tumours.
Several questions remain regarding the optimal combin-
ation of OVs and CAR T-cell ACT. Will optimal adminis-
tration of OVs (and indeed CAR T-cells) be achieved by
local intra-tumoural injection or by systemic parenteral
delivery? Which CAR intracellular domain/construct may
be most conducive to synergy with specific OVs? Which
tumours are likely to be optimal targets for synergistic com-
bination? Will the optimal combined use of (engineered)
OV differ in the treatment of “hot” (inflamed) as opposed
to “cold” non-inflamed tumours? Other questions relate to
the optimal disease setting within which such experimental
approaches could eventually be deployed. Whilst advanced
cancer has proven to be more resistant, early stage disease
(such as localised breast cancer, which is commonly cured
with a combination of surgery, radiotherapy and hormone
therapy) remains challenging to treat using cellular therap-
ies, due to the requirement for highly toxic lymphodeplet-
ing conditioning (often incorporating cyclophosphamide
with fludarabine) with or without the administration of
systemic cytokines such as IL-2. There is indirect evidence,
however, that OV infection may obviate the need for such
pre-conditioning and intra-tumoural delivery of OVs and
CAR T-cells would be expected to permit the treatment of
early stage disease in a more controlled and less toxic
manner. Alternatively, there may be a particular role for the
synergistic combination of OVs and CAR T-cell therapy in
patients who have progressed following immune check-
point blockade. Review of patients who have responded to
anti-CTLA-4 and/or anti-PD-1/PD-L1 axis blockade over
many years has yielded valuable data about the mechanisms
of acquired resistance [42]. As a final consideration, OV
infection may prove to be more efficacious in tumours with
an acquired impairment of IFNγ signalling (e.g. through
mutation of the JAK-STAT pathway), whereas CAR T-cell
therapy may provide a more attractive option for patients
whose tumours have lost MHC class I expression (e.g. due
to β2-microglobulin mutations). Certainly, the rapid tech-
nical advancement and falling cost of developing genetically
engineered biotherapies heralds the imminent arrival of
individualised cellular and viral products for the treatment
of cancer.
Conclusions
The potential for combining OVs, CAR T-cell therapy and
an additional immunotherapeutic strategy are practically
limitless. Furthermore, due to the broad applicability of
these techniques the ability to synergistically combine OVs
with TCR-engineered ACT (e.g. targeting cancer testis anti-
gens such as NY-ESO-1) may also be considered. Triplet or
quadruplet combinations may be envisaged using systemic-
ally delivered immune checkpoint inhibitors and/or co-
stimulatory agonists, or indeed other immunomodulatory
agents such as IDO inhibitors, TLR or STING agonists,
Smac mimetics, A2R antagonists, anti-angiogenic agents or
even novel DGK and SHP-1 inhibitors. The timing and
scheduling of these combination strategies is likely to be
crucial. For example, studies have shown that administering
an anti-CTLA-4 mAb on the same day as delivering a
vaccinia OV can impair efficacy of the latter, presumably
due to an enhanced anti-viral effect. Such combinations are
also likely to be dependent upon the family and strain of
the OV used, and indeed the synergistic combination of an
anti-CTLA-4 mAb was found to be strain specific [222]. In
short, the future is likely to yield a rich seam of translational
and clinical research in which these two exciting technolo-
gies are combined to tackle the pressing need for improved
treatments for patients with advanced solid tumours.
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